BiotechTube

Azithromycin SR + Amoxiclav

Pre-clinicalTerminated
1 views this week 0 watching💤 Quiet
Interest: 18/100
18
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Community-Acquired Pneumonia

Conditions

Community-Acquired Pneumonia

Trial Timeline

Apr 1, 2010 → Dec 1, 2010

NCT ID
NCT01032694

About Azithromycin SR + Amoxiclav

Azithromycin SR + Amoxiclav is a pre-clinical stage product being developed by Pfizer for Community-Acquired Pneumonia. The current trial status is terminated. This product is registered under clinical trial identifier NCT01032694. Target conditions include Community-Acquired Pneumonia.

What happened to similar drugs?

1 of 8 similar drugs in Community-Acquired Pneumonia were approved

Approved (1) Terminated (0) Active (7)
✅IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacinPfizerApproved
🔄Ceftaroline + CeftriaxonePfizerPhase 3
🔄Azithromycin microspheres 2.0 single dosePfizerPhase 3
🔄Azithromycin SRPfizerPhase 3
🔄tigecyclinePfizerPhase 3
🔄Tigecycline + LevofloxacinPfizerPhase 3
🔄Omadacycline + MoxifloxacinZai LabPhase 3

Hype Score Breakdown

Clinical
3
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01032694Pre-clinicalTerminated

Competing Products

9 competing products in Community-Acquired Pneumonia

See all competitors
ProductCompanyStageHype Score
ONO-5046Na + ONO-5046NaOno PharmaceuticalPhase 2
35
Ceftaroline + CeftriaxonePfizerPhase 3
40
Azithromycin microspheres 2.0 single dosePfizerPhase 3
40
IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacinPfizerApproved
43
Azithromycin SRPfizerPhase 3
40
tigecyclinePfizerPhase 3
40
Tigecycline + LevofloxacinPfizerPhase 3
40
Omadacycline + MoxifloxacinZai LabPhase 3
41
ceftobiprole medocaril + IV standard-of-care cephalosporinBasilea PharmaceuticaPhase 3
34